Logotipo de HISPANA
Logotipo del Ministerio de Cultura
  • Què és Hispana?
  • Cerca
  • Directori de col.leccions
  • Contacte
  • ca
    • Español
    • Euskara
    • English
    • Galego
    • Català
    • Valencià
Está en:  › Dades de registre
Linked Open Data
Limosilactobacillus fermentum CECT5716: Mechanisms and Therapeutic Insights
Identificadores del recurso
Rodríguez-Sojo, M.J.; Ruiz-Malagón, A.J.; Rodríguez-Cabezas, M.E.; Gálvez, J.; Rodríguez-Nogales, A. Limosilactobacillus fermentum CECT5716: Mechanisms and Therapeutic Insights. Nutrients 2021, 13, 1016. [https://doi.org/10.3390/nu13031016]
http://hdl.handle.net/10481/68227
10.3390/nu13031016
Procedència
(Ilíberis: fondo bibliográfico histórico de la Universidad de Granada)

Fitxa

Títol:
Limosilactobacillus fermentum CECT5716: Mechanisms and Therapeutic Insights
Tema:
Probiotic
Limosilactobacillus fermentum CECT5716
Immunomodulation
Dysbiosis
Mechanism of action
Gastrointestinal diseases
Microbiota
Descripció:
This work was supported by the Junta de Andalucía (CTS 164) and Instituto de Salud Carlos III (PI19/01058) with funds from the European Union.
M.J. Rodríguez-Sojo is a predoctoral fellow from University of Granada (“Programa de Doctorado en Biomedicina”); A.J. Ruiz-Malagón is a predoctoral fellow from Formación de Profesorado Universitario Program (“Programa de Doctorado en Medicina Clínica y Salud Pública”), and A. Rodríguez-Nogales is a postdoctoral fellow of Instituto de Salud Carlos III (Miguel Servet Program).
Probiotics microorganisms exert their health-associated activities through some of the following general actions: competitive exclusion, enhancement of intestinal barrier function, production of bacteriocins, improvement of altered microbiota, and modulation of the immune response. Among them, Limosilactobacillus fermentum CECT5716 has become one of the most promising probiotics and it has been described to possess potential beneficial effects on inflammatory processes and immunological alterations. Different studies, preclinical and clinical trials, have evidenced its anti-inflammatory and immunomodulatory properties and elucidated the precise mechanisms of action involved in its beneficial effects. Therefore, the aim of this review is to provide an updated overview of the effect on host health, mechanisms, and future therapeutic approaches.
Junta de Andalucia CTS 164
Instituto de Salud Carlos III European Commission PI19/01058
European Commission
Idioma:
English
Autor/Productor:
Rodríguez Sojo, María Jesús
Ruiz Malagón, Antonio Jesús
Rodríguez Cabezas, María Elena
Gálvez Peralta, Julio Juan
Rodríguez Nogales, Alba
Editor:
MDPI
Drets:
Atribución 3.0 España
http://creativecommons.org/licenses/by/3.0/es/
info:eu-repo/semantics/openAccess
Data:
2021-04-30T08:38:54Z
2021-03-21
Tipo de recurso:
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion

oai_dc

Descarregar XML

    <?xml version="1.0" encoding="UTF-8" ?>

  1. <oai_dc:dc schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">

    1. <dc:title>Limosilactobacillus fermentum CECT5716: Mechanisms and Therapeutic Insights</dc:title>

    2. <dc:creator>Rodríguez Sojo, María Jesús</dc:creator>

    3. <dc:creator>Ruiz Malagón, Antonio Jesús</dc:creator>

    4. <dc:creator>Rodríguez Cabezas, María Elena</dc:creator>

    5. <dc:creator>Gálvez Peralta, Julio Juan</dc:creator>

    6. <dc:creator>Rodríguez Nogales, Alba</dc:creator>

    7. <dc:subject>Probiotic</dc:subject>

    8. <dc:subject>Limosilactobacillus fermentum CECT5716</dc:subject>

    9. <dc:subject>Immunomodulation</dc:subject>

    10. <dc:subject>Dysbiosis</dc:subject>

    11. <dc:subject>Mechanism of action</dc:subject>

    12. <dc:subject>Gastrointestinal diseases</dc:subject>

    13. <dc:subject>Microbiota</dc:subject>

    14. <dc:description>This work was supported by the Junta de Andalucía (CTS 164) and Instituto de Salud Carlos III (PI19/01058) with funds from the European Union.</dc:description>

    15. <dc:description>M.J. Rodríguez-Sojo is a predoctoral fellow from University of Granada (“Programa de Doctorado en Biomedicina”); A.J. Ruiz-Malagón is a predoctoral fellow from Formación de Profesorado Universitario Program (“Programa de Doctorado en Medicina Clínica y Salud Pública”), and A. Rodríguez-Nogales is a postdoctoral fellow of Instituto de Salud Carlos III (Miguel Servet Program).</dc:description>

    16. <dc:description>Probiotics microorganisms exert their health-associated activities through some of the following general actions: competitive exclusion, enhancement of intestinal barrier function, production of bacteriocins, improvement of altered microbiota, and modulation of the immune response. Among them, Limosilactobacillus fermentum CECT5716 has become one of the most promising probiotics and it has been described to possess potential beneficial effects on inflammatory processes and immunological alterations. Different studies, preclinical and clinical trials, have evidenced its anti-inflammatory and immunomodulatory properties and elucidated the precise mechanisms of action involved in its beneficial effects. Therefore, the aim of this review is to provide an updated overview of the effect on host health, mechanisms, and future therapeutic approaches.</dc:description>

    17. <dc:description>Junta de Andalucia CTS 164</dc:description>

    18. <dc:description>Instituto de Salud Carlos III European Commission PI19/01058</dc:description>

    19. <dc:description>European Commission</dc:description>

    20. <dc:date>2021-04-30T08:38:54Z</dc:date>

    21. <dc:date>2021-04-30T08:38:54Z</dc:date>

    22. <dc:date>2021-03-21</dc:date>

    23. <dc:type>info:eu-repo/semantics/article</dc:type>

    24. <dc:type>info:eu-repo/semantics/publishedVersion</dc:type>

    25. <dc:identifier>Rodríguez-Sojo, M.J.; Ruiz-Malagón, A.J.; Rodríguez-Cabezas, M.E.; Gálvez, J.; Rodríguez-Nogales, A. Limosilactobacillus fermentum CECT5716: Mechanisms and Therapeutic Insights. Nutrients 2021, 13, 1016. [https://doi.org/10.3390/nu13031016]</dc:identifier>

    26. <dc:identifier>http://hdl.handle.net/10481/68227</dc:identifier>

    27. <dc:identifier>10.3390/nu13031016</dc:identifier>

    28. <dc:language>eng</dc:language>

    29. <dc:rights>Atribución 3.0 España</dc:rights>

    30. <dc:rights>http://creativecommons.org/licenses/by/3.0/es/</dc:rights>

    31. <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>

    32. <dc:publisher>MDPI</dc:publisher>

    </oai_dc:dc>

edm

Descarregar XML

    <?xml version="1.0" encoding="UTF-8" ?>

  1. <rdf:RDF schemaLocation="http://www.w3.org/1999/02/22-rdf-syntax-ns# http://www.europeana.eu/schemas/edm/EDM.xsd">

    1. <edm:ProvidedCHO about="http://hdl.handle.net/10481/68227">

      1. <dc:creator>Rodríguez Sojo, María Jesús</dc:creator>

      2. <dc:creator>Ruiz Malagón, Antonio Jesús</dc:creator>

      3. <dc:creator>Rodríguez Cabezas, María Elena</dc:creator>

      4. <dc:creator>Gálvez Peralta, Julio Juan</dc:creator>

      5. <dc:creator>Rodríguez Nogales, Alba</dc:creator>

      6. <dc:date>2021-03-21</dc:date>

      7. <dc:description>This work was supported by the Junta de Andalucía (CTS 164) and Instituto de Salud Carlos III (PI19/01058) with funds from the European Union.</dc:description>

      8. <dc:description>M.J. Rodríguez-Sojo is a predoctoral fellow from University of Granada (“Programa de Doctorado en Biomedicina”); A.J. Ruiz-Malagón is a predoctoral fellow from Formación de Profesorado Universitario Program (“Programa de Doctorado en Medicina Clínica y Salud Pública”), and A. Rodríguez-Nogales is a postdoctoral fellow of Instituto de Salud Carlos III (Miguel Servet Program).</dc:description>

      9. <dc:description>Probiotics microorganisms exert their health-associated activities through some of the following general actions: competitive exclusion, enhancement of intestinal barrier function, production of bacteriocins, improvement of altered microbiota, and modulation of the immune response. Among them, Limosilactobacillus fermentum CECT5716 has become one of the most promising probiotics and it has been described to possess potential beneficial effects on inflammatory processes and immunological alterations. Different studies, preclinical and clinical trials, have evidenced its anti-inflammatory and immunomodulatory properties and elucidated the precise mechanisms of action involved in its beneficial effects. Therefore, the aim of this review is to provide an updated overview of the effect on host health, mechanisms, and future therapeutic approaches.</dc:description>

      10. <dc:identifier>http://hdl.handle.net/10481/68227</dc:identifier>

      11. <dc:language>eng</dc:language>

      12. <dc:publisher>MDPI</dc:publisher>

      13. <dc:title>Limosilactobacillus fermentum CECT5716: Mechanisms and Therapeutic Insights</dc:title>

      14. <dc:type>info:eu-repo/semantics/article</dc:type>

      15. <edm:type>TEXT</edm:type>

      </edm:ProvidedCHO>

    2. <ore:Aggregation about="http://hdl.handle.net/10481/68227#aggregation">

      1. <edm:aggregatedCHO resource="http://hdl.handle.net/10481/68227" />
      2. <edm:dataProvider>DIGIBUG. Repositorio Institucional de la Universidad de Granada</edm:dataProvider>

      3. <edm:isShownAt resource="http://hdl.handle.net/10481/68227" />
      4. <edm:isShownBy resource="https://digibug.ugr.es/bitstream/10481/68227/1/nutrients-13-01016-v3.pdf" />
      5. <edm:provider>Hispana</edm:provider>

      6. <edm:rights resource="http://creativecommons.org/licenses/by/4.0/" />

      </ore:Aggregation>

    3. <edm:WebResource about="https://digibug.ugr.es/bitstream/10481/68227/1/nutrients-13-01016-v3.pdf">

      1. <edm:rights resource="http://creativecommons.org/licenses/by/4.0/" />

      </edm:WebResource>

    </rdf:RDF>

Hispana

Portal d'accés al patrimoni digital i l'agregador nacional de continguts a Europeana

Contacte

Accedeix al nostre formulari i et contestarem el més aviat

Contacte

X

Tweets by Hispana_roai

Facebook

HISPANA
© Ministeri de Cultura
  • Avís legal